Hunting Hill Global Capital LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Hunting Hill Global Capital LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 4,259 shares of the biopharmaceutical company’s stock, valued at approximately $1,694,000. Alnylam Pharmaceuticals accounts for 1.2% of Hunting Hill Global Capital LLC’s investment portfolio, making the stock its 16th biggest holding.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. HM Payson & Co. bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $29,000. Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Ameriflex Group Inc. bought a new position in Alnylam Pharmaceuticals during the third quarter worth about $32,000. Finally, Manchester Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 72 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on ALNY. HC Wainwright restated a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 4th. Jefferies Financial Group restated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Citigroup began coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective for the company. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Finally, Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $463.13.

Insider Buying and Selling

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 7,740 shares of company stock valued at $2,420,214. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $282.72 on Thursday. The firm has a market cap of $37.75 billion, a price-to-earnings ratio of 77.25 and a beta of 0.29. The company has a 50 day moving average of $302.00 and a 200-day moving average of $339.75. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 1-year low of $276.94 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.44) earnings per share. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.